Sequel Med Tech and Abbott to Integrate Future Glucose-Ketone Sensor with twiist™ AID System

What You Should Know: 

– Sequel Med Tech, a company developing state-of-the-art insulin delivery technologies, announced a commercial development agreement with Abbott. 

– The collaboration aims for the future integration of Sequel’s twiist Automated Insulin Delivery (AID) System, powered by Tidepool, with Abbott’s glucose-ketone sensor, which is currently under development.

– The planned integration is designed to significantly improve outcomes for people living with type 1 diabetes by combining continuous glucose monitoring with ketone sensing capabilities. This will enable earlier detection of rising ketones, a critical factor in preventing diabetic ketoacidosis (DKA).

Advancing Diabetes Management with Integrated Ketone Sensing

The agreement underscores Sequel Med Tech’s commitment to providing more choice, flexibility, and confidence to individuals managing type 1 diabetes. By incorporating ketone sensing into the AID system, users will have a more comprehensive view of their metabolic state.

“By integrating the twiist AID System with Abbott’s future glucose-ketone sensor, Sequel will be able to offer people with diabetes greater choice and the potential for improved outcomes in managing their care,” said Sequel CEO and Co-Founder Alan Lotvin, M.D.. “twiist was designed to rapidly identify interruptions in insulin delivery, so combining this with early identification of rising ketones could help people living with diabetes react more quickly and more confidently. Through this collaboration, we are redefining what people living with diabetes can expect from an AID system”.

The twiist AID System: Precision, Flexibility, and User Choice

The twiist AID System, cleared for individuals aged six and up with type 1 diabetes, features proprietary iiSure Technology. This technology directly measures the volume of insulin delivered with each micro-dose, utilizing four checkpoints to measure insulin quantity and alert users to blockages up to nine times faster than competing AID systems.

The system’s twiist Loop algorithm, based on Tidepool Loop technology designed by and for people with diabetes, automatically adjusts basal insulin delivery based on real-time sensor readings and predicted glucose levels. Users of the twiist system will be able to select from compatible CGM systems to best suit their individual needs, including Abbott’s FreeStyle Libre® 3 Plus sensor and, in the future, the Senseonics Eversense 365. Abbott’s glucose-ketone sensor will be added as an option once the product is cleared for use and available in the U.S..

The Critical Role of Early Ketone Detection

Regular measurement of ketones has been shown to reduce the risk of diabetic ketoacidosis, a serious complication of diabetes that occurs when the body produces high levels of blood acids called ketones[cite: 1]. Early detection of rising ketones allows for timely intervention, which can prevent the progression to DKA.

Future Integration and AvailabilityThe twiist AID System is set to be commercially available in the second quarter of 2025. The integration with Abbott’s glucose-ketone sensor will follow once Abbott’s sensor is cleared for use and made available in the U.S.. Patients interested in learning more about twiist and its availability can visit www.twiist.com.